

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT																								
NATURE OF CONVEYANCE:	ASSIGNMENT																								
CONVEYING PARTY DATA																									
<table border="1"> <thead> <tr> <th>Name</th> <th>Execution Date</th> </tr> </thead> <tbody> <tr> <td>Immunocore Limited</td> <td>07/18/2013</td> </tr> </tbody> </table>		Name	Execution Date	Immunocore Limited	07/18/2013																				
Name	Execution Date																								
Immunocore Limited	07/18/2013																								
RECEIVING PARTY DATA																									
<table border="1"> <tr> <td>Name:</td> <td>Adaptimmune Limited</td> </tr> <tr> <td>Street Address:</td> <td>9400 Garsington Road</td> </tr> <tr> <td>Internal Address:</td> <td>Oxford Business Park</td> </tr> <tr> <td>City:</td> <td>Oxford</td> </tr> <tr> <td>State/Country:</td> <td>UNITED KINGDOM</td> </tr> <tr> <td>Postal Code:</td> <td>OX4 2HN</td> </tr> </table>		Name:	Adaptimmune Limited	Street Address:	9400 Garsington Road	Internal Address:	Oxford Business Park	City:	Oxford	State/Country:	UNITED KINGDOM	Postal Code:	OX4 2HN												
Name:	Adaptimmune Limited																								
Street Address:	9400 Garsington Road																								
Internal Address:	Oxford Business Park																								
City:	Oxford																								
State/Country:	UNITED KINGDOM																								
Postal Code:	OX4 2HN																								
PROPERTY NUMBERS Total: 11																									
<table border="1"> <thead> <tr> <th>Property Type</th> <th>Number</th> </tr> </thead> <tbody> <tr> <td>Patent Number:</td> <td>7329731</td> </tr> <tr> <td>Patent Number:</td> <td>7763718</td> </tr> <tr> <td>Patent Number:</td> <td>7569664</td> </tr> <tr> <td>Patent Number:</td> <td>7666604</td> </tr> <tr> <td>Patent Number:</td> <td>7608410</td> </tr> <tr> <td>Patent Number:</td> <td>8361794</td> </tr> <tr> <td>Patent Number:</td> <td>8378074</td> </tr> <tr> <td>Patent Number:</td> <td>8217144</td> </tr> <tr> <td>Patent Number:</td> <td>8017730</td> </tr> <tr> <td>Application Number:</td> <td>12603255</td> </tr> <tr> <td>Application Number:</td> <td>12443078</td> </tr> </tbody> </table>		Property Type	Number	Patent Number:	7329731	Patent Number:	7763718	Patent Number:	7569664	Patent Number:	7666604	Patent Number:	7608410	Patent Number:	8361794	Patent Number:	8378074	Patent Number:	8217144	Patent Number:	8017730	Application Number:	12603255	Application Number:	12443078
Property Type	Number																								
Patent Number:	7329731																								
Patent Number:	7763718																								
Patent Number:	7569664																								
Patent Number:	7666604																								
Patent Number:	7608410																								
Patent Number:	8361794																								
Patent Number:	8378074																								
Patent Number:	8217144																								
Patent Number:	8017730																								
Application Number:	12603255																								
Application Number:	12443078																								
CORRESPONDENCE DATA																									
Fax Number:	2124077799																								
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>																									

CH \$440.00 7329731

Phone: 212 407-7700
Email: ipdocketny@vedderprice.com
Correspondent Name: Thomas J. Kowalski
Address Line 1: 1633 Broadway
Address Line 2: Vedder Price P.C.
Address Line 4: New York, NEW YORK 10019

ATTORNEY DOCKET NUMBER:	44172.00.1000
NAME OF SUBMITTER:	Sarah Marcano
Signature:	/sarah marcano/
Date:	07/18/2013

Total Attachments: 3
source=AssignmentHalfRight#page1.tif
source=AssignmentHalfRight#page2.tif
source=AssignmentHalfRight#page3.tif

ASSIGNMENT

Immunocore Limited, is a corporation incorporated in the United Kingdom (company number 6456207), whose registered office address is 57c Milton Park, Abingdon, Oxfordshire, OX14 4RX, United Kingdom, having the entire right, title and interest in the Letters Patents and Published Applications hereinafter recited in the attached Schedule A, the "Assignor"; and **Adaptimmune Limited** is a corporation incorporated in the United Kingdom (company number 6456741), whose registered office address is, 9400 Garsington Road, Oxford Business Park, Oxford, OX4 2HN, United Kingdom and which, together with their successors and assigns are hereinafter called, the "Assignee."


Now, therefore, for valuable consideration furnished by Assignee to Assignor, receipt and sufficiency of which is hereby acknowledged, Assignor hereby, without reservation:

1. Assigns and conveys to and confirms in Assignee a **one-half undivided interest** in its right, title and interest in the Letters Patents and Published Applications hereinafter recited in the attached Schedule A, and to said Letters Patent on said published applications, including all divisional, renewal, substitute and continuation applications, and any and all Letters Patent and reissues and extensions of Letters Patent granted for published applications;
2. Authorizes and requests the Commissioner of Patents of the United States of America to issue or transfer all said Letters Patent and Published Applications hereinafter recited in the attached Schedule A, to Assignee, as assignee of the one-half undivided interest in its right, title and interest in said Letters Patent and Published Applications hereinafter recited in the attached Schedule A;
3. Warrants that Assignor has not knowingly conveyed to others any right in said Letters Patent and Published Applications hereinafter recited in the attached Schedule A or any license to use the same or to make, use or sell anything embodying or utilizing any of said Letters Patent and Published Applications hereinafter recited in the attached Schedule A; and that Assignor has good right to assign the same to Assignee without encumbrance;
4. Assignor agrees to do, upon Assignee's request and at its expense, but without additional consideration to Assignor, all acts reasonably serving to assure that the said Letters Patent and Published Applications hereinafter recited in the attached Schedule A shall be held and enjoyed by Assignee as fully and entirely as the same could have been held and enjoyed by

Assignor or representatives if this assignment had not been made; and particularly to execute and deliver to Assignee all lawful application documents including petitions, specifications, and oaths, and all assignments, disclaimers, and lawful affidavits in form and substance as may be requested by Assignee; to communicate to Assignee all facts known relating to said Letters Patent and Published Applications hereinafter recited in the attached Schedule A or the history thereof; and to furnish Assignee with any and all documents, photographs, models, samples and other physical exhibits in its control or in the control of its legal representatives and which may be useful for establishing the facts of conceptions, disclosures, and reduction to practice of said Letters Patent and Published Applications hereinafter recited in the attached Schedule A.

Signed on behalf of Immunocore Limited:


Date: 18-7-13



James Noble
Chief Executive Officer
Immunocore Limited

Signed on behalf of Adaptimmune Limited:

Date: 18-7-2013



Helen Tayton-Martin
Chief Operating Officer
Adaptimmune Limited

SCHEDULE A

LETTERS PATENT AND PUBLISHED APPLICATIONS

Letters Patent/Published Application Nos.	Title
7329731	Soluble T Cell Receptor
7763718	Soluble T Cell Receptor
7569664	Single Chain Recombinant T Cell Receptor
7666604	Modified T Cell Receptor
7608410	Method Of Improving T Cell Receptors
8361794	Cells Expressing A Modified T Cell Receptor
8378074	High Affinity HIV T Cell Receptors
8217144	High Affinity Melan-A T Cell Receptors
8017730	T Cells Receptors Which Specifically Bind to VYGFVRACL-HLA-24
2010/0113300	T Cell Receptor Display
2010/0166722	T Cell Therapies